Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNeoVCA: Personalized Neoantigen Vaccine + Pembrolizumab in Advanced Solid Tumors
NCT05269381Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2022
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, open-label trial in solid tumor, triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 1 more (5 cohorts), sponsored by Mayo Clinic. Primary endpoints: Maximally Tolerated Dose at 2 years, Dose Limiting Toxicity at 2 years and 3 more. Started Mar 2022; status: recruiting.
02
Conditions
solid tumortriple negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)invasive lobular carcinoma (ILC)
Beyond the preview
Go deeper on NCT05269381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269381.